Nasal Provocation Test With Lysine-Acetylsalicylate (ASA) in Patients With Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) Hypersensitivity
NCT ID: NCT00815126
Last Updated: 2010-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
34 participants
INTERVENTIONAL
2008-11-30
2009-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Mucocutaneous symptoms from NSAIDs
Lysine-ASA Nasal ProvocationTest
Lysine-ASA 80 µl (16 mg of aspirin) will be installed in both nostrils with pipette
Respiratory symptoms from NSAIDs
Lysine-ASA Nasal ProvocationTest
Lysine-ASA 80 µl (16 mg of aspirin) will be installed in both nostrils with pipette
NSAIDs tolerant individuals
Lysine-ASA Nasal ProvocationTest
Lysine-ASA 80 µl (16 mg of aspirin) will be installed in both nostrils with pipette
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lysine-ASA Nasal ProvocationTest
Lysine-ASA 80 µl (16 mg of aspirin) will be installed in both nostrils with pipette
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Nasal corticosteroids/Oral corticosteroids/Leukotriene modifiers for 1 week
* Short-acting antihistamines for 3 days
* Nasal a-mimetics/Oral a-mimetics/Local cromones for 24 hours
* Contraindicated for nasal provocation test: pregnant, exacerbation of allergic rhinitis/asthma, having upper respiratory tract infection within 2 weeks prior to the test, having nose surgery within 8 weeks prior to the test, having severe systemic disease(s)
* Having factors interfere nasal provocation test with Lysine-ASA such as massive nasal polyp, nasal septal perforation, total nasal obstruction at least 1 nostril
15 Years
70 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chulalongkorn University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Chulalongkorn University
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jettanong Klaewsongkram, MD
Role: PRINCIPAL_INVESTIGATOR
Chulalongkorn University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Faculty of Medicine, Chulalongkorn University
Bangkok, , Thailand
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Chula-ARC 002/08
Identifier Type: -
Identifier Source: org_study_id